Vical turns to vaccine pipeline after PhIII fail; CSL posts record net profits;

> Vical has shifted focus to its developmental vaccines after its melanoma immunotherapy failed Phase III. Piece

> Australian vaccine maker CSL posted a 19% rise in annual net profits to hit a record high of $1.2 billion. News

> Researchers have generated an Ad5 vector that is unaffected by neutralizing antibodies in mice. Abstract

> Cedars-Sinai Medical Center is running a Phase I trial to see if Copaxone can help Alzheimer's patients by stimulating immune cells. Release

> Researchers in Singapore have posted promising preclinical results for a dengue fever vaccine. Article

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.